Transcept to resubmit insomnia drug US NDA once again
This article was originally published in Scrip
Executive Summary
Transcept Pharmaceuticals has reported plans to resubmit an NDA for its insomnia drug, Intermezzo (zolpidem tartrate sublingual tablet) to the US FDA by the end of the month, following a meeting with the regulator.